Co-Diagnostics, Inc. Breakthrough CoPrimer™ Technology to be Featured at PAG XXVIII
07 January 2020 - 10:30PM
Business Wire
Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular
diagnostics company with a unique, patented platform for the
development of diagnostic tests, announced today that the Company’s
groundbreaking Co-Diagnostics CoPrimer™ technology will be featured
at the International Plant & Animal Genome XXVIII conference,
held on January 11-15 in San Diego, CA.
The evaluation of BHQplex™ CoPrimers in flexible PCR-based
genotyping will be presented by a representative of Bayer - Crop
Science on Monday, January 13, in a presentation titled “CoPrimer
Assays for Multiplex PCR.” According to the presentation abstract,
Bayer evaluated the patented technology’s ability to enable robust
and flexible multiplexing for PCR-based genotyping in several
assays. This included successfully testing their performance in
many different combinations and plex-levels using qPCR, end-point
and digital PCR. BHQplex CoPrimers utilize the Company’s patented
CoPrimer technology as branded by LGC Biosearch, whose footprint
covers over 200 countries.
The Company intends to provide additional information concerning
the importance of these findings following the presentation.
More information about the PAG conference can be found on the
conference website.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets a new,
state-of-the-art diagnostics technology. The Company’s technology
is utilized for tests that are designed using the detection and/or
analysis of nucleic acid molecules (DNA or RNA). The Company also
uses its proprietary technology to design specific tests to locate
genetic markers for use in industries other than infectious disease
and license the use of those tests to specific customers.
Forward-Looking Statements:
This press release contains forward-looking statements.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Forward-looking statements in
this release may include statements regarding the (i) use of
funding proceeds, (ii) expansion of product distribution, (iii)
acceleration of initiatives in certain verticals or markets, (iv)
capital resources and runway needed to advance the Company’s
products and markets, (v) increased sales in the near-term, (vi)
flexibility in managing the Company’s balance sheet, (vii)
anticipation of business expansion, and (viii) benefits in research
and worldwide accessibility of the CoPrimer technology and its
cost-saving and scientific advantages. Forward-looking statements
are subject to inherent uncertainties, risks and changes in
circumstances. Actual results may differ materially from those
contemplated or anticipated by such forward-looking statements.
Readers of this press release are cautioned not to place undue
reliance on any forward-looking statements. The Company does not
undertake any obligation to update any forward-looking statement
relating to matters discussed in this press release, except as may
be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200107005381/en/
Andrew Benson Head of Investor Relations +1 801-438-1036
investors@codiagnostics.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Apr 2024 to May 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From May 2023 to May 2024